In an odd twist for a drug developer, Avant Immunotherapeutics hailed news that its experimental therapy for high-risk cardiac surgery utilizing cardiopulmonary bypass failed to meet a primary endpoint in a women-only drug trial. Researchers said the results confirmed earlier data that indicated the therapy worked for men but not for women.
"These data confirm the results in females from our previous TP10 trial. Therefore, given the strong efficacy data in males shown in this previous study, there is a clear clinical development pathway for a males-only indication for TP10 in cardiac bypass surgery," said Una S. Ryan, Ph.D., CEO of Avant. "Males represent 75 percent of the U.S. market opportunity in cardiac bypass surgery. We believe that the TP10 program is now well positioned for a males-only cardiac bypass surgery indication and we expect to partner the TP10 program for this indication."
- see this release for more
PLUS: Avant also announced that drug partner GlaxoSmithKline Biologics had received European approval for Rotarix, the first rotavirus vaccine available to children in Europe for the prevention of gastroenteritis caused by rotavirus. Release